Tackling Unmet
Medical Needs

There is a continually high level of UMN regarding rare diseases with a small number of patients and with no established method of treatment. Within Daiichi Sankyo Group, we actively undertake initiatives to develop pharmaceuticals for these rare diseases with significant social needs.


Research & Development

Specific initiatives

testtesttset

Specific initiatives

Our Company’s Efforts to Limit the Spread of the Virus that Causes COVID-19

The Daiichi Sankyo group is actively engaged in various measures and initiatives such as, but not limited to, contributing to vaccination and drug research and development, ensuring a continuous supply of the Daiichi Sankyo group products, and providing disaster relief supports.

View More